Current Molecular Pharmacology

Scope & Guideline

Fostering Dialogue in the Evolving World of Pharmacology

Introduction

Welcome to the Current Molecular Pharmacology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Current Molecular Pharmacology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1874-4672
PublisherBENTHAM SCIENCE PUBL LTD
Support Open AccessNo
CountryUnited Arab Emirates
TypeJournal
Convergefrom 2008 to 2024
AbbreviationCURR MOL PHARMACOL / Curr. Molec. Pharmacol.
Frequency7 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressEXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES

Aims and Scopes

Current Molecular Pharmacology focuses on the intersection of molecular biology and pharmacology, aiming to elucidate the mechanisms of drug action and the molecular basis of disease. The journal promotes innovative research that advances our understanding of pharmacological interventions at a molecular level, with a strong emphasis on translational research that bridges laboratory findings to clinical applications.
  1. Molecular Mechanisms of Drug Action:
    The journal extensively covers studies that investigate the molecular pathways through which drugs exert their effects, including signal transduction, gene expression modulation, and metabolic pathways.
  2. Therapeutic Targets in Disease:
    Research articles often focus on identifying and validating novel therapeutic targets for various diseases, particularly cancer, neurological disorders, and metabolic diseases.
  3. Pharmacological Innovations:
    Current Molecular Pharmacology emphasizes the development of new pharmacological agents and therapeutic strategies, including natural products and novel drug formulations.
  4. Translational Research:
    The journal seeks to publish research that translates molecular pharmacology findings into potential clinical applications, showcasing studies that move from bench to bedside.
  5. Interdisciplinary Approaches:
    It encourages interdisciplinary research that combines pharmacology with fields such as genetics, molecular biology, and biochemistry to provide a comprehensive understanding of drug action.
Current Molecular Pharmacology has identified several trending and emerging themes that reflect the latest advancements and interests in the field of pharmacology. These themes highlight the journal's commitment to addressing contemporary challenges and exploring new frontiers in molecular pharmacology.
  1. Cancer Pharmacology and Targeted Therapies:
    A significant increase in publications focusing on cancer pharmacology, particularly on targeted therapies, immunotherapy, and the molecular mechanisms underlying tumor progression and metastasis.
  2. Neuropharmacology and Neurological Disorders:
    There is a rising interest in neuropharmacology, with a focus on drug development for neurological disorders, including Alzheimer’s disease and neuroinflammation, emphasizing molecular pathways and therapeutic potential.
  3. Natural Products and Novel Drug Development:
    Research on natural products as sources of novel pharmacological agents is trending, emphasizing their mechanisms of action and potential therapeutic applications.
  4. MicroRNAs and Gene Regulation:
    The exploration of microRNAs in the regulation of gene expression and their implications in various diseases, particularly cancer and metabolic disorders, is gaining prominence.
  5. Metabolic Disorders and Pharmacological Interventions:
    Emerging themes include the pharmacological management of metabolic disorders, with a focus on molecular mechanisms and new therapeutic strategies aimed at obesity and diabetes.

Declining or Waning

As the field of molecular pharmacology evolves, certain themes have become less prominent in recent publications of Current Molecular Pharmacology. These declining scopes reflect shifting research interests and advancements in technology and methodologies.
  1. Traditional Pharmacotherapy:
    There is a noticeable decline in studies focused solely on traditional pharmacotherapy approaches without molecular insights. The current trend favors studies that incorporate molecular mechanisms and novel therapeutic strategies.
  2. Basic Pharmacokinetics and Pharmacodynamics:
    Research articles that primarily discuss basic pharmacokinetics and pharmacodynamics without integrating molecular insights or novel drug mechanisms appear to be waning in frequency.
  3. Single-Agent Studies:
    The journal has seen fewer publications focused on the efficacy of single-agent therapies. Instead, there is a growing emphasis on combination therapies and multi-targeted approaches.
  4. Animal Models with Limited Molecular Relevance:
    Studies using animal models that do not explore molecular mechanisms or pathways are becoming less common, as there is a shift towards more relevant models that provide insights applicable to human conditions.

Similar Journals

KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY

Fostering excellence in physiological and pharmacological studies.
Publisher: KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGYISSN: 1226-4512Frequency: 6 issues/year

Welcome to the Korean Journal of Physiology & Pharmacology, a pivotal academic platform dedicated to advancing the disciplines of physiology and pharmacology. Published by the esteemed Korean Journal of Physiology & Pharmacology, this journal has been disseminating valuable research findings since its inception in 1997 and continues to be a critical resource for researchers, professionals, and students in South Korea and beyond. With an ISSN of 1226-4512 and E-ISSN of 2093-3827, it offers insights into various aspects of drug action and physiological mechanisms. Although this journal currently does not subscribe to Open Access, it plays a vital role in bridging the gap between experimental and clinical studies, receiving commendations for its quality. In the 2023 Scopus rankings, it is notably positioned in the Q3 quartile for Pharmacology and Q4 for Physiology, reflecting its commitment to excellence. As the journal converges towards its comprehensive coverage in 2024, it remains a cornerstone for those looking to engage deeply with critical developments in these fields.

MEDICINAL RESEARCH REVIEWS

Elevating Biomedical Knowledge through Rigorous Review
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

ACTA PHARMACOLOGICA SINICA

Championing High-Impact Research in Pharmacology
Publisher: NATURE PUBL GROUPISSN: 1671-4083Frequency: 12 issues/year

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

BIOCHEMICAL PHARMACOLOGY

Advancing drug discovery through biochemical insights.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0006-2952Frequency: 12 issues/year

BIOCHEMICAL PHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, stands as a leading international journal devoted to the advancing field of biochemical pharmacology. Since its inception in 1958, the journal has continuously offered a platform for innovative research, delivering critical insights into the interaction between biochemical processes and pharmaceutical applications, and now converges towards its 2024 edition. With an impressive Q1 ranking in both Biochemistry and Pharmacology categories, it ranks 32nd out of 313 in Pharmacology and Toxicology, and 58th out of 438 in Biochemistry according to Scopus, showcasing its significant impact within the scientific community. Researchers and professionals rely on this journal to keep abreast of essential developments, given its robust peer-review process and a comprehensive selection of articles that span experimental studies, clinical trials, and theoretical analyses. Although not an Open Access journal, it remains pivotal for those seeking to advance their knowledge in the dynamic fields of biochemistry and pharmacology. With its high impact factor and emphasis on quality research, BIOCHEMICAL PHARMACOLOGY continues to be an invaluable resource for students, researchers, and industry professionals striving to make breakthroughs in drug development and therapeutic strategies.

Chinese Journal of Natural Medicines

Innovating the Future of Natural Therapies
Publisher: CHINESE JOURNAL NATURAL MEDICINESISSN: 2095-6975Frequency: 6 issues/year

The Chinese Journal of Natural Medicines, published by the esteemed CHINESE JOURNAL NATURAL MEDICINES, plays a pivotal role in the exploration and advancement of complementary and alternative medicine. With an ISSN of 2095-6975 and an E-ISSN of 1875-5364, this journal is recognized for its commitment to high-quality research and innovative findings in the realms of drug discovery and miscellaneous medical fields. Operating from China, it has earned a prestigious reputation in the academic community, achieving Q1 status in Complementary and Alternative Medicine and Q2 rankings in both Drug Discovery and Miscellaneous Medicine as of 2023, solidifying its influence within the scientific discourse. Researchers and professionals will find valuable insights here as the journal explores the intersection of traditional natural medicines with modern pharmacological science, making it an essential resource for anyone dedicated to the field. With a convergence period from 2004 to 2024, the journal continues to champion open dialogue and disseminate significant findings critical for the development of effective natural therapies.

CNS & Neurological Disorders-Drug Targets

Transforming Research into Therapeutic Solutions
Publisher: BENTHAM SCIENCE PUBLISSN: 1871-5273Frequency: 8 issues/year

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION

Fostering Collaboration in Molecular Biology
Publisher: TAYLOR & FRANCIS LTDISSN: 1079-9893Frequency: 6 issues/year

JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, published by TAYLOR & FRANCIS LTD, is a premier academic journal dedicated to advancing our understanding of receptor biology and signal transduction mechanisms. With an ISSN of 1079-9893 and an E-ISSN of 1532-4281, this journal has maintained a reputable standing since its inception in 1980, continually addressing pivotal topics in biochemistry, cell biology, and molecular biology. As evidenced by its 2023 Scopus rankings, which place it in the 64th percentile for Biochemistry and Genetics and Molecular Biology, JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION remains a vital source for cutting-edge research, providing insights that are essential for both academic and practical applications. Although the journal currently offers limited open access options, it stands out in the Q2 and Q3 quartiles of its respective categories, making it an invaluable resource for researchers, professionals, and students aiming to stay abreast of the latest findings and methodologies in receptor and signaling research. The journal's commitment to disseminating high-quality research underscores its significance within the scientific community, fostering innovation and collaboration across disciplines.

MINI-REVIEWS IN MEDICINAL CHEMISTRY

Fostering Knowledge Exchange for Future Medical Breakthroughs.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-5575Frequency: 20 issues/year

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

ARCHIVES OF PHARMACAL RESEARCH

Pioneering breakthroughs in drug discovery and molecular medicine.
Publisher: PHARMACEUTICAL SOC KOREAISSN: 0253-6269Frequency: 12 issues/year

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.

European Journal of Pharmacology

Fostering interdisciplinary collaboration in the realm of pharmacology.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.